Toboroz
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945· 1/2. fázis· Biojiva LLC· Forrás
Toboroz
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
NCT07867080· 3. fázis· 4D Molecular Therapeutics· Forrás
Toboroz
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
NCT07592273· 2/3. fázis· AbbVie· Forrás
Fut, nem toboroz
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· 3. fázis· EyePoint Pharmaceuticals, Inc.· Forrás
Toboroz
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
NCT07392255· 1/2. fázis· Complement Therapeutics· Forrás
Toboroz
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065· 3. fázis· AbbVie· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· 2. fázis· ONL Therapeutics· Forrás
Toboroz
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234· 1/2. fázis· Sanofi· Forrás
Toboroz
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07160179· 1/2. fázis· AbbVie· Forrás
Toboroz
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137· Complement Therapeutics· Forrás
Toboroz
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· 3. fázis· 4D Molecular Therapeutics· Forrás
Toboroz
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162· i-Lumen Scientific AUS PTY LTD· Forrás
Toboroz
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
NCT06942520· 2. fázis· Sierra Eye Associates· Forrás
Fut, nem toboroz
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048· 4. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· 3. fázis· 4D Molecular Therapeutics· Forrás
Fut, nem toboroz
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773· Astellas Pharma Global Development, Inc.· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· 3. fázis· Ocular Therapeutix, Inc.· Forrás
Fut, nem toboroz
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
NCT06660667· 1/2. fázis· Sanofi· Forrás
Fut, nem toboroz
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· 3. fázis· EyePoint Pharmaceuticals, Inc.· Forrás
Toboroz
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT06817343· 1. fázis· Exegenesis Bio· Forrás
Fut, nem toboroz
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· 3. fázis· Annexon, Inc.· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958· 3. fázis· Ocular Therapeutix, Inc.· Forrás
Fut, nem toboroz
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· 2. fázis· Kyowa Kirin Co., Ltd.· Forrás
Toboroz
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
NCT05626114· 2. fázis· Genentech, Inc.· Forrás
Fut, nem toboroz
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854· 1. fázis· Genentech, Inc.· Forrás
Meghívásos bevonás
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
NCT05481827· 2. fázis· Gyroscope Therapeutics Limited· Forrás
Fut, nem toboroz
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
NCT05300724· Genentech, Inc.· Forrás
Fut, nem toboroz
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
NCT05296447· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102· 4. fázis· Genentech, Inc.· Forrás
Fut, nem toboroz
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636· 3. fázis· AbbVie· Forrás
Meghívásos bevonás
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
NCT05210803· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251· 4. fázis· Genentech, Inc.· Forrás
Toboroz
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270· 1/2. fázis· 4D Molecular Therapeutics· Forrás
Fut, nem toboroz
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921· 2/3. fázis· AbbVie· Forrás
Fut, nem toboroz
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT04514653· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT04108156· 3. fázis· Hoffmann-La Roche· Forrás
Meghívásos bevonás
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801· 2. fázis· AbbVie· Forrás
Toboroz
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251· 3. fázis· Hoffmann-La Roche· Forrás